Added to YB: 2026-03-25
Pitch date: 2026-03-23
ALLO [bullish]
Allogene Therapeutics, Inc.
-7.14%
current return
Author Info
No bio for this author
Company Info
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Market Cap
$504.6M
Pitch Price
$2.38
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.85
P/E
-2.39
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
ALLO . Allogene Therapeutics .
ALLO: Off-the-shelf CAR-T platform by Kite Pharma founder (sold to Gilead for $11.9B). Allogeneic approach cuts cost 95% from $373-410K to $10-20K/dose, produces 20K-60K doses/yr. Apr: ALPHA3 pivotal trial interim data on cema-cel in lymphoma. Jun: ALLO-329 autoimmune POC data w/ Dagger tech. $505M mkt cap, 18/21 analysts bullish, last pure-play allo CAR-T. Active M&A space (BMS, Gilead, Novartis, Roche). Belldegrun's track record: builds to sell.
Read full article (1 min)